Jones Financial Companies Lllp Acquires Shares of 206,505 Amneal Pharmaceuticals, Inc. $AMRX

Key Points

• Jones Financial Companies Lllp invested $1.73 million in AMNEAL PHARMACEUTICALS, acquiring 206,505 shares during the first quarter.
• Several institutional investors increased their stakes in AMNEAL, with Bank of America growing its ownership by 218.8% in the fourth quarter.
• Goldman Sachs initiated coverage of AMNEAL PHARMACEUTICALS with a "buy" rating and a price target of $12.00.

Jones Financial Companies Lllp purchased a new position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 206,505 shares of the company's stock, valued at approximately $1,731,000. Jones Financial Companies Lllp owned 0.07% of Amneal Pharmaceuticals as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. GAMMA Investing LLC increased its holdings in Amneal Pharmaceuticals by 5,975.0% in the 1st quarter. GAMMA Investing LLC now owns 3,159 shares of the company's stock worth $26,000 after buying an additional 3,107 shares in the last quarter. Headlands Technologies LLC purchased a new position in Amneal Pharmaceuticals in the first quarter worth about $31,000. Amalgamated Bank boosted its position in Amneal Pharmaceuticals by 33.0% in the first quarter. Amalgamated Bank now owns 5,511 shares of the company's stock worth $46,000 after purchasing an additional 1,367 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in Amneal Pharmaceuticals in the fourth quarter worth about $52,000. Finally, Xponance Inc. boosted its position in Amneal Pharmaceuticals by 16.1% in the first quarter. Xponance Inc. now owns 13,183 shares of the company's stock worth $110,000 after purchasing an additional 1,828 shares during the last quarter. 31.82% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, The Goldman Sachs Group started coverage on Amneal Pharmaceuticals in a research report on Friday, June 6th. They issued a "buy" rating and a $12.00 target price on the stock. Five equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $11.60.

Amneal Pharmaceuticals Stock Performance

NASDAQ:AMRX traded down $0.21 during trading hours on Monday, reaching $9.79. The stock had a trading volume of 1,377,949 shares, compared to its average volume of 1,673,730. Amneal Pharmaceuticals, Inc. has a 52 week low of $6.68 and a 52 week high of $10.34. The company has a 50 day moving average price of $8.83 and a two-hundred day moving average price of $8.19. The stock has a market capitalization of $3.07 billion, a PE ratio of 979.98 and a beta of 1.19.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported $0.23 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.17 by $0.06. Amneal Pharmaceuticals had a negative return on equity of 189.49% and a net margin of 0.12%. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.700-0.750 EPS. Equities research analysts predict that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current year.

Insider Buying and Selling

In other news, Director John Kiely sold 32,000 shares of the business's stock in a transaction that occurred on Wednesday, August 27th. The stock was sold at an average price of $9.23, for a total transaction of $295,360.00. Following the transaction, the director owned 225,433 shares of the company's stock, valued at approximately $2,080,746.59. The trade was a 12.43% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Nikita Shah sold 114,492 shares of the business's stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $9.66, for a total value of $1,105,992.72. Following the transaction, the executive vice president directly owned 152,743 shares in the company, valued at approximately $1,475,497.38. This represents a 42.84% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 609,206 shares of company stock worth $5,700,625. 26.56% of the stock is owned by company insiders.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.